Structural racism plays a fundamental role in the unequal distribution of lung cancer risk factors. Hemoglobin and platelets are associated with overall survival in patients with myelofibrosis following allogeneic HSCT. Treatment-naïve myelofibrosis patients who received navitoclax plus ruxolitinib saw a significant reduction in spleen ... Dr. Eugenia Alleva discusses a study that found women with dysmenorrhea have increased cardiovascular risk. Dr. Mona S. Jhaveri discusses the importance of Lung Cancer Awareness Month, recent breakthroughs in lung cancer, and more. Dr. Benjamin Horne discusses a study that showed increases in PM2.5 during the summer and winter impact heart health. Dr. Ijeoma Eleazu talks about the harmful impact of cumulative stress on cardiovascular health. Mark McDonough, CEO of ChromaCode, discusses an innovative, high-definition PCR assay for enhanced detection of NSCLC. Dr. Christian Ruff on positive results from the AZALEA-TIMI 71 study of patients with AF at moderate to high risk of stroke. James K. Min, MD, founder and CEO of Cleerly, talks about improved screening for heart disease using a digital care platform. Dr. Babak Nazer discusses an experimental, leadless pacemaker that shows great potential in improving patient QoL. Asbestos exposure led to a higher incidence of asbestos-related lung cancers in naval personnel. Drs. Jim List and Puneet Mohan discuss the Librexia program and the benefits of milvexian treatment. Dr. Melissa Johnson, of Sarah Cannon, discusses lung cancer trials to keep an eye on and unmet needs in lung cancer. Dr. Karthik Gonuguntla discusses the study he led on cardiovascular health disparities in American Indian adults. Stenting improves chest pain, exercise capacity, and quality of life among patients with stable chest pain. A study indicates that blood transfusions for anemic patients hospitalized with heart attack may improve patient outcomes. Semaglutide reduced major CVD risk by 20% in adults with overweight or obesity, but not diabetes. COVID-19 infection increases the risk of thromboembolic events, particularly MI, in patients with prior MI. Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events independent of ASCVD risk scores.